Allogene Therapeutics announced the appointment of Zachary Roberts M.D., Ph.D. to Executive Vice President of Research and Development. The hiring of Dr. Roberts, who previously held clinical leadership roles at Instil Bio and Kite Pharma, underscores the Company’s commitment to rapidly advancing its pipeline following recent clinical data illustrating the potential of its AlloCAR T product candidates to induce deep and durable responses. Dr. Roberts will assume the responsibilities of Rafael Amado, M.D. who has resigned to pursue other opportunities. Arun Balakumaran, M.D., Chief Medical Officer and Barbra Sasu, Ph.D., Chief Scientific Officer will report to Dr. Roberts.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALLO:
- Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
- Allogene Therapeutics downgraded to Underperform from Buy at BofA
